Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	36.04	28.36	34.81	29.43	39.14	43.84
Short-Term Investments	547.19	696.93	388.78	275.52	369.11	150.59
Cash & Short-Term Investments	583.22	725.28	423.6	304.95	408.25	194.42
Cash Growth	-22.85%	71.22%	38.91%	-25.30%	109.98%	201.98%
Receivables	0.09	0.7	2.63	0.35	0.17	1.8
Prepaid Expenses	21.03	21.18	5.47	12.39	2.42	1.62
Total Current Assets	604.34	747.16	431.69	317.69	410.84	197.84
Property, Plant & Equipment	7.55	8.24	6.64	7.75	6.52	7.26
Other Intangible Assets	27.19	27.19	27.19	27.19	27.19	30.69
Other Long-Term Assets	9.36	9.75	0.11	0.1	0.1	0.04
Total Assets	648.44	792.34	465.63	352.74	444.65	235.84
Accounts Payable	4.27	3.27	3.49	3.34	1.23	1.05
Accrued Expenses	39.72	33.84	22.03	12.84	12	8.46
Current Portion of Leases	1.55	1.45	1.61	1.45	1.75	1.33
Current Unearned Revenue	-	0.01	3.06	0.06	0.43	-
Other Current Liabilities	0.93	0.93	0.93	0.93	1.12	3.37
Total Current Liabilities	46.47	39.5	31.13	18.61	16.53	14.21
Long-Term Leases	1.07	2.36	0.93	2.59	1.3	2.15
Other Long-Term Liabilities	2.54	3.47	4.4	5.33	7.35	10.12
Total Liabilities	50.08	45.34	36.46	26.53	25.18	26.48
Common Stock	0.07	0.07	0.06	0.05	0.05	0.04
Additional Paid-In Capital	2,327	2,299	1,823	1,581	1,561	1,280
Retained Earnings	-1,733	-1,555	-1,397	-1,256	-1,144	-1,073
Comprehensive Income & Other	3.77	3.31	3.31	1.26	1.89	2.59
Shareholders' Equity	598.36	747.01	429.17	326.2	419.48	209.36
Total Liabilities & Equity	648.44	792.34	465.63	352.74	444.65	235.84
Total Debt	2.62	3.81	2.54	4.03	3.04	3.48
Net Cash (Debt)	580.6	721.47	421.06	300.92	405.21	190.94
Net Cash Growth	-22.89%	71.35%	39.92%	-25.74%	112.22%	214.43%
Net Cash Per Share	8.75	11.20	8.69	6.42	9.45	6.44
Filing Date Shares Outstanding	66.45	66.38	55.9	47.21	46.74	39.61
Total Common Shares Outstanding	66.45	66.37	55.88	47.2	46.73	39.6
Working Capital	557.87	707.66	400.57	299.08	394.31	183.64
Book Value Per Share	9.01	11.25	7.68	6.91	8.98	5.29
Tangible Book Value	571.17	719.82	401.98	299.01	392.29	178.67
Tangible Book Value Per Share	8.60	10.84	7.19	6.33	8.39	4.51
Machinery	-	17.39	16.01	15.26	14.51	14.61
Construction In Progress	-	0.14	0.79	0.5	0.63	0.34
Leasehold Improvements	-	10.29	9.65	9.61	9.53	10.1

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q